Data elements by category

Figures  |  Boxes  |  Tables

Figures

Figure 1: Introduction of methadone maintenance and high-dose buprenorphine treatment in EU Member States, candidate countries and Norway

Figure 2: Last year prevalence of cannabis use among young adults (aged 15–34 and 15–24)

Figure 3: Trends in last year prevalence of cannabis use among young adults (aged 15–34)

Figure 4: Last year prevalence of amphetamine use among young adults (aged 15–34)

Figure 5: Last year prevalence of ecstasy use among young adults (aged 15–34)

Figure 6: Last year prevalence of cocaine use among all adults (aged 15–64) and young adults (aged 15–34 and 15–24)

Figure 7: Trends in last year prevalence of cocaine use among young adults (aged 15–34)

Figure 8: Estimates of the prevalence of problem opioid and stimulant use, 2000–04 (rate per 1 000 population aged 15–64)

Figure 9: Trends in the prevalence of problem opioid use, 1995–2004 (rate per 1 000 population aged 15–64)

Figure 10: HIV prevalence in tested injecting drug users, 2003–04

Figure 11: Priority for and extent of use of selected measures to prevent infectious diseases in drug users, according to national expert opinion: summary for responding countries

Figure 12: Proportion of acute drug-related deaths occurring under the age of 25 years in 2002

Figure 13: Long-term trend in acute drug-related deaths, 1985–2004

Figure 14: Distribution of 'new' and 'all' clients requesting treatment according to their primary drug

Figure 15: Use of drugs in the last year by different user groups in the general population aged 15–34

Trends in retail prices of drugs in Europe, 1999–2004